Literature DB >> 18623073

Binase and other microbial RNases as potential anticancer agents.

Alexander A Makarov1, Alexander Kolchinsky, Olga N Ilinskaya.   

Abstract

Some RNases possess preferential cytotoxicity against malignant cells. The best known of these RNases, onconase, was isolated from frog oocytes and is in clinical trials as anticancer therapy. Here we propose an alternative platform for anticancer therapy based on T1 RNases of microbial origin, in particular binase from Bacillus intermedius and RNase Sa from Streptomyces aureofaciens. We discuss their advantages and the most promising directions of research for their potential clinical applications. (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18623073     DOI： 10.1002/bies.20789

Source DB:  PubMed          Journal:  Bioessays        ISSN： 0265-9247            Impact factor:   4.345


  29 in total

1.  Anti-EGFR-miniantibody-barnase immunoconjugate is highly toxic for human tumor cells.

Authors:  E F Edelweiss; T G Balandin; O A Stremovskiy; S M Deyev; R V Petrov
Journal:  Dokl Biochem Biophys       Date:  2010-10-20       Impact factor: 0.788

Review 2.  Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor.

Authors:  Elena M Glinka
Journal:  Tumour Biol       Date:  2015-04-01

Review 3.  Microbial ribonucleases (RNases): production and application potential.

Authors:  E Esin Hameş; Tuğçe Demir
Journal:  World J Microbiol Biotechnol       Date:  2015-10-03       Impact factor: 3.312

4.  Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.

Authors:  Taras G Balandin; Evelina Edelweiss; Natalia V Andronova; Elena M Treshalina; Alexander M Sapozhnikov; Sergey M Deyev
Journal:  Invest New Drugs       Date:  2009-09-30       Impact factor: 3.850

5.  Molecular docking and dynamics simulations of A.niger RNase from Aspergillus niger ATCC26550: for potential prevention of human cancer.

Authors:  Gundampati Ravi Kumar; Rajasekhar Chikati; Santhi Latha Pandrangi; Manoj Kandapal; Kirti Sonkar; Neeraj Gupta; Chaitanya Mulakayala; Medicherla V Jagannadham; Chitta Suresh Kumar; Sunita Saxena; Mira Debnath Das
Journal:  J Mol Model       Date:  2012-09-16       Impact factor: 1.810

Review 6.  Ribonucleases as potential modalities in anticancer therapy.

Authors:  Wojciech Ardelt; Barbara Ardelt; Zbigniew Darzynkiewicz
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

7.  Ribonuclease binase inhibits primary tumor growth and metastases via apoptosis induction in tumor cells.

Authors:  Nadezhda L Mironova; Irina Y Petrushanko; Olga A Patutina; Aexandra V Sen'kova; Olga V Simonenko; Vladimir A Mitkevich; Oleg V Markov; Marina A Zenkova; Alexander A Makarov
Journal:  Cell Cycle       Date:  2013-06-10       Impact factor: 4.534

8.  Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis.

Authors:  Francesco Acquati; Marta Lualdi; Sabrina Bertilaccio; Laura Monti; Giovanna Turconi; Marco Fabbri; Annalisa Grimaldi; Achille Anselmo; Antonio Inforzato; Angelo Collotta; Laura Cimetti; Cristina Riva; Laura Gribaldo; Paolo Ghia; Roberto Taramelli
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

9.  Determinants of eukaryal cell killing by the bacterial ribotoxin PrrC.

Authors:  Birthe Meineke; Beate Schwer; Raffael Schaffrath; Stewart Shuman
Journal:  Nucleic Acids Res       Date:  2010-09-19       Impact factor: 16.971

10.  Modern Technologies for Creating Synthetic Antibodies for Clinical application.

Authors:  S M Deyev; E N Lebedenko
Journal:  Acta Naturae       Date:  2009-04       Impact factor: 1.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.